Kestra Medical Technologies reported third‑quarter fiscal 2026 revenue of $24.6 million, a 63% year‑over‑year increase that beat the consensus estimate of $23.03 million by $1.57 million. Gross margin expanded to 52.6%, up from 43.4% in the same quarter a year earlier, and the company’s earnings per share were –$0.61, missing the consensus estimate of –$0.60 by $0.01 (or –$0.42 by some estimates).
The revenue surge was driven by a 58% year‑over‑year rise in prescriptions for the company’s ASSURE wearable defibrillator platform, totaling 5,462 prescriptions in Q3 FY26. Market‑share gains in the U.S. commercial segment and a higher mix of in‑network patients contributed to the top‑line growth, while the company’s rental‑based business model continued to deliver attractive unit economics.
Gross margin expansion reflects a combination of cost‑efficiency initiatives and volume leverage. Management highlighted that the margin growth is due to “continued cost efficiencies and a higher mix of in‑network patients.” The company has achieved nine consecutive quarters of sequential gross‑margin improvement, a milestone that underscores its ability to scale while maintaining pricing power.
The EPS miss can be attributed to increased operating expenses, including non‑recurring professional fees and costs associated with the equity offering that closed on December 4, 2025. The equity raise added $291 million in cash and equivalents as of January 31, 2026, extending the company’s runway but also adding one‑time charges that weighed on earnings.
Guidance for fiscal 2026 was raised to $93 million from the previously revised $91 million, reflecting confidence in sustained prescription growth and market‑share gains from the ASSURE platform. The equity raise and the company’s strong cash position support the higher outlook, while the management team remains optimistic about reaching 70%+ gross margins in the coming years.
"Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to over 52%," said Brian Webster, President and CEO. "We also continued to execute on several key operational objectives, including rapid growth of the commercial organization, release of compelling primary results from our FDA post‑approval study, fortification of our balance sheet with an equity offering, and entrance into a strategic collaboration with Biobeat Technologies." CFO Vaseem Mahboob added, "We have now expanded our gross margin sequentially nine quarters in a row." CEO Webster noted, "Our math points to about 70% to 75% of that coming from installed base or current market share shift as we win market share, and about 25% of it coming from actual new prescribers." "We are seeing nice operating leverage in our business," he added. "We remain confident that Kestra is on a path to 70%+ gross margins over the next few years," and concluded, "The fundamentals of Kestra's story and business remain strong." Investors responded positively to the results, citing the strong revenue growth, margin expansion, and raised guidance as key drivers of confidence.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.